121 related articles for article (PubMed ID: 10570511)
21. Embolia cutis medicamentosa following interferon beta injection.
Koontz D; Alshekhlee A
Mult Scler; 2007 Nov; 13(9):1203-4. PubMed ID: 17967846
[No Abstract] [Full Text] [Related]
22. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
[TBL] [Abstract][Full Text] [Related]
23. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
[TBL] [Abstract][Full Text] [Related]
24. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
25. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?
Hügle T; Gratzl S; Daikeler T; Frey D; Tyndall A; Walker UA
Ann Rheum Dis; 2009 Jan; 68(1):47-50. PubMed ID: 18203763
[TBL] [Abstract][Full Text] [Related]
26. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
[TBL] [Abstract][Full Text] [Related]
27. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.
Buttmann M; Goebeler M; Toksoy A; Schmid S; Graf W; Berberich-Siebelt F; Rieckmann P
J Neuroimmunol; 2005 Nov; 168(1-2):175-82. PubMed ID: 16126281
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
Feinstein A; O'Connor P; Feinstein K
J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
[TBL] [Abstract][Full Text] [Related]
30. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
31. Interferon-beta1b in multiple sclerosis.
Buttmann M; Rieckmann P
Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
[TBL] [Abstract][Full Text] [Related]
32. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
35. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
[TBL] [Abstract][Full Text] [Related]
36. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
37. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy.
Macbeth AE; Kendall BR; Smith A; Saldanha G; Harman KE
Br J Dermatol; 2007 Sep; 157(3):624-5. PubMed ID: 17596164
[No Abstract] [Full Text] [Related]
38. Cotton wool spots associated with interferon beta-1 alpha therapy.
Longmuir R; Lee AG; Rouleau J
Semin Ophthalmol; 2007; 22(1):49-53. PubMed ID: 17366120
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
[TBL] [Abstract][Full Text] [Related]
40. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis.
Ekstein D; Linetsky E; Abramsky O; Karussis D
Neurology; 2005 Aug; 65(3):456-8. PubMed ID: 16087915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
